Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) is a clinical-stage biopharmaceutical company developing proprietary oral delivery technologies for biologics and drugs. The company's website is www.ranitherapeutics.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Rani Therapeutics Holdings, Inc. does
In the company’s own words
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) is a clinical-stage biopharmaceutical company developing proprietary oral delivery technologies for biologics and drugs. The company's website is www.ranitherapeutics.com.
Rani operates through its consolidated subsidiary, Rani Therapeutics, LLC, and focuses on advancing a drug-agnostic oral delivery platform called the RaniPill capsule, designed to deliver a wide variety of drug substances including antibodies, proteins, peptides, and oligonucleotides. The company has developed two configurations of its platform: the RaniPill GO, designed to deliver up to three milligrams of drug in microtablet form with high bioavailability, and the RaniPill HC, a high-capacity version intended to enable delivery of drug payloads up to two hundred microliters in liquid form.
The RaniPill capsule operates as an orally ingestible pill approximately the size of a standard fish oil or calcium supplement. It features a proprietary pH-sensitive coating that protects the drug through the stomach's acidic environment and deploys in the jejunum portion of the small intestine. Upon deployment, a self-inflating balloon orients a microneedle approximately perpendicular to the intestinal wall, delivering the drug payload directly into the highly vascularized intestinal tissue for absorption into the bloodstream.
Rani's pipeline includes multiple product candidates in various development stages. RT-114, a RaniPill HC capsule containing a GLP-1/GLP-2 dual agonist for obesity treatment, initiated Phase 1 clinical trials in December 2025. RT-116 contains semaglutide for obesity treatment and is in preclinical development. RT-111, containing an ustekinumab biosimilar for inflammatory conditions, completed a Phase 1 study. RT-105, an adalimumab biosimilar for psoriatic arthritis, is paused pending strategic review. RT-117, developed through a collaboration with Chugai Pharmaceutical for hemophilia treatment, represents a partnered program.
The company has established strategic collaborations, including a partnership with Chugai Pharmaceutical and ProGen Co., Ltd. Rani maintains vertically integrated manufacturing capabilities and plans to continue scaling and optimizing manufacturing processes through expanded automation. The company has not generated revenue from commercial products and remains in early clinical development stages with no approved products.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN JOSE, CA
- Fiscal year end
- December
- CIK
- 1856725
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Rani Therapeutics Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Rani Therapeutics Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Rani Therapeutics Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Rani Therapeutics Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Rani Therapeutics Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”